Randomized Controlled Trial of Osmotic-Release Methylphenidate With Cognitive-Behavioral Therapy in Adolescents With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders.

Authors :: Riggs, Paula D.
Winhusen, Theresa
Davies, Robert D.
Leimberger, Jeffrey D.
Mikulich-Gilbertson, Susan
Klein, Constance
Macdonald, Marilyn
Lohman, Michelle
Bailey, Genie L.
Haynes, Louise
Jaffee, William B.
Hamilton, Nancy
Hodgkins, Candace
Whitmore, Elizabeth
Trello-Rishel, Kathlene
Tamm, Leanne
Acosta, Michelle C.
Royer-Malvestuto, Charlotte
Subramaniam, Geetha
Fishman, Marc
Source :: Journal of the American Academy of Child & Adolescent Psychiatry. Sep2011, Vol. 50 Issue 9, p903-914. 12p.
Publication Year :: 2011
Abstract: The article presents a study examining the randomized controlled trial of osmotic-release methylphenidate (OROS-PHM) in adolescents with attention-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUD). It evaluates the efficacy and safety of osmotic-release methylphenidate compared with placebo for ADHD and SUD. A 16-week randomized controlled multi-site trial of OROS-MPH has been conducted against placebo. OROS-MPH has been found with no greater efficacy than placebo for ADHD.

Subjects :: *METHYLPHENIDATE
*DRUG efficacy
*RANDOMIZED controlled trials
*ATTENTION-deficit hyperactivity disorder
*SUBSTANCE abuse
*PLACEBOS

Full Text Access

Tools